Review: Gastric cancer-Clinical aspects.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9605411 Publication Model: Print Cited Medium: Internet ISSN: 1523-5378 (Electronic) Linking ISSN: 10834389 NLM ISO Abbreviation: Helicobacter Subsets: MEDLINE

Publication: Oxford : Wiley-Blackwell
Original Publication: Malden, MA : Wiley-Blackwell, c1996-

Host-Pathogen Interactions*; Antineoplastic Agents/*therapeutic use ; Helicobacter Infections/*complications ; Stomach Neoplasms/*drug therapy ; Stomach Neoplasms/*epidemiology; Biomedical Research/trends ; China/epidemiology ; Hong Kong/epidemiology ; Humans ; Incidence ; United States/epidemiology

Gastric cancer (GC) was responsible for over 1 000 000 new cases in 2018 and an estimated 783 000 deaths, making it still the fifth most frequently diagnosed cancer and the third leading cause of cancer deaths in both sexes worldwide. Divergent trends for GC incidence were observed in the USA. Incidence rates, particularly for non-cardia GC, were stable or increasing among persons aged <50 years. In an analysis of data from a public hospital database in Hong Kong, treatment of Helicobacter pylori infection was associated with a lower risk of GC, particularly in older subjects who received treatment ≥10 years before. Based on the results of a 16-year endoscopy-based follow-up eradication trial, patients with incomplete-type intestinal metaplasia (IM) should receive endoscopic surveillance upon H. pylori eradication therapy. Updated guidelines on the endoscopic surveillance of preneoplastic conditions of the stomach (MAPS II) have been published. In the RAINFALL trial, the addition of ramucirumab to a backbone chemotherapy as a first-line regimen failed to improve overall survival (OS) of patients with metastatic disease. Also, pembrolizumab did not prolong OS when compared to paclitaxel in the second-line treatment of patients with advanced GC or esophagogastric junction (EGJ) cancer. Trifluridine/tipiracil improved OS by 2.1 months in the third or further treatment line of patients with advanced GC. In a systematic investigation conducted on Chinese patients with GC, CLDN18-ARHGAP26/6 fusion was associated with signet-ring cell content and was prognostic for a worse outcome and predictive for no benefit from oxaliplatin/fluoropyrimidine-based chemotherapy. Organoid cultures represent an appealing model that may be applied for therapy response testing in the near future.
(© 2019 John Wiley & Sons Ltd.)

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Wang Z, Graham DY, Khan A, et al. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47(3):966-975.
Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137-e147.
Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23:e12518.
Moayyedi P, Veldhuyzen van Zanten SJO, Hookey L, Armstrong D, Jones N, Leontiadis GI. Proton pump inhibitors and gastric cancer: association is not causation. Gut. 2019;68(8):1529-1530.
Laterza L, Scaldaferri F, Gasbarrini A. Risk factors for gastric cancer: is it time to discard PPIs? Gut. 2019;68(1):176-177.
Suissa S, Suissa A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. Gut. 2018;67(12):2228-2229.
Zhou C-B, Fang J-Y. Several aspects in study design need further consideration. Gut. 2018;67(11):2070-2071.
Suzuki H, Matsuzaki J. Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. Gut. 2018;67(11):2071-2072.
Heinrichs SKM, Hess T, Becker J, et al. Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level. Cancer Med. 2018;7(10):5057-5065.
Hishida A, Ugai T, Fujii R, et al. GWAS analysis reveals a significant contribution of PSCA to the risk of Heliobacter pylori -induced gastric atrophy. Carcinogenesis. 2019;40:661-668.
Leung WK, Wong IOL, Cheung KS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155(1):67-75.
Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019;68(1):11-17.
Rugge M, Genta RM, Fassan M, et al. OLGA Gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018;113(11):1621-1628.
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(04):365-388.
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67:2092-2096.
Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239-1246.
Selgrad M, Bornschein J, Kandulski A, et al. Combined gastric and colorectal cancer screening-A new strategy. Int J Mol Sci. 2018;19(12):3854.
Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957.
Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420-435.
Shitara K, Özgüroğlu M, Bang Y-J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-133.
Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437-1448.
Venerito M. S-1 in patients with advanced esophagogastric adenocarcinoma: results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. Drugs R & D. 2019;19:141-148.
Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, et al. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018;98:23-29.
Shu Y, Zhang W, Hou Q, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nat Commun. 2018;9(1):2447.
Seidlitz T, Merker SR, Rothe A, et al. Human gastric cancer modelling using organoids. Gut. 2019;68(2):207-217.

Keywords: Helicobacter pylori; cancer of the esophagogastric junction; epidemiology; gastric cancer; surveillance; therapy

0 (Antineoplastic Agents)

Date Created: 20190906 Date Completed: 20191231 Latest Revision: 20200108

20240829

10.1111/hel.12643

31486238